Dengue Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Abivax, Plex Pharmaceuticals, Codagenix, Emergex Vaccines, Visterra, Merck Sharp

The Dengue Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Dengue Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dengue Market.

Some of the key takeaways from the Dengue Pipeline Report:

• Companies across the globe are diligently working toward developing novel Dengue treatment therapies with a considerable amount of success over the years. 
• Dengue companies working in the treatment market are Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Emergex Vaccines, Visterra, Merck Sharp & Dohme LLC, Janssen Research & Development, Merck & Co., Takeda, and others, are developing therapies for the Dengue treatment 

• Emerging Dengue therapies in the different phases of clinical trials are- Research programme: antiRNA-virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, PepGNP Dengue, VIS513, V181, JNJ-64281802, TV003, V 503, and others are expected to have a significant impact on the Dengue market in the coming years.   
• In March 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice.
• In January 2022, Janssen Research & Development initiated a Phase IIa, Randomized, Double-blind,Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ64281802 in Participants With Confirmed Dengue Fever. The purpose of this study is to investigate the antiviralactivity of JNJ-64281802 versus placebo in terms of reduction of dengue virus (DENV) ribonucleic acid (RNA) inprimary DENV infection.

Dengue Overview

The Aedes aegypti mosquito transmits the four dengue viruses that cause the sickness. According to the Centre for Disease Control and Prevention (CDC), dengue fever affects at least 400 million people worldwide each year. Due to the intensity of the muscular and joint pain and spasms, it is also known as breakbone fever, dandy fever, or seven-day fever.

Get a Free Sample PDF Report to know more about Dengue Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dengue-pipeline-insight

Emerging Dengue Drugs Under Different Phases of Clinical Development Include:

• Research programme: antiRNA virus therapeutics Kino Pharma
• ABX220: Abivax
• VIS 513: Visterra
• TAK-003: Takeda
• AT 752: Atea Pharmaceuticals
• Infectious diseases therapeutics Programme: Plex Pharmaceuticals
• CDX DENV: Codagenix
• PepGNP Dengue: Emergex Vaccines
• VIS513: Visterra
• V181: Merck Sharp & Dohme LLC
• JNJ-64281802: Janssen Research & Development
• TV003: Merck & Co.
• V 503: Takeda

Route of Administration

Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Dengue Pipeline Therapeutics Assessment

• Dengue Assessment by Product Type
• Dengue By Stage and Product Type
• Dengue Assessment by Route of Administration
• Dengue By Stage and Route of Administration
• Dengue Assessment by Molecule Type
• Dengue by Stage and Molecule Type

DelveInsight’s Dengue Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dengue product details are provided in the report. Download the Dengue pipeline report to learn more about the emerging Dengue therapies

Some of the key companies in the Dengue Therapeutics Market include:

Key companies developing therapies for Dengue are – Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, Takeda Pharmaceutical Company Limited, and others.

Dengue Pipeline Analysis:

The Dengue pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Dengue with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Treatment.
• Dengue key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dengue Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dengue drugs and therapies

Dengue Pipeline Market Drivers

• Fastest spreading mosquito-borne viral disease, search of novel tools and innovative strategies to interrupt transmission of dengue, integration of vector management approaches is encouraged are some of the important factors that are fueling the Dengue Market.

Dengue Pipeline Market Barriers

• However, challenging research due to multiple stereotypes, disease risks may change and shift with climate change in tropical and subtropical areas and other factors are creating obstacles in the Dengue Market growth.

Scope of Dengue Pipeline Drug Insight    

• Coverage: Global
• Key Dengue Companies: Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Emergex Vaccines, Visterra, Merck Sharp & Dohme LLC, Janssen Research & Development, Merck & Co., Takeda, and others
• Key Dengue Therapies: Research programme: antiRNA-virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, PepGNP Dengue, VIS513, V181, JNJ-64281802, TV003, V 503, and others
• Dengue Therapeutic Assessment: Dengue current marketed and Dengue emerging therapies
• Dengue Market Dynamics: Dengue market drivers and Dengue market barriers 

Request for Sample PDF Report for Dengue Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services